Recombinant Human Keratinocyte Growth Factor in Unrelated and Related Transplants

University of Michigan50 enrolled

Overview

This is a single arm dose escalation study of recombinant human keratinocyte growth factor given to patients undergoing allogeneic bone marrow transplantation who are at high risk for graft versus host disease (GVHD).

Completion date provided represents the completion date of the grant per OOPD records

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Enrollment

Conditions

Graft Versus Host Disease

Interventions

recombinant human keratinocyte growth factorDRUG

Eligibility

Sex: ALLMin age: 3 YearsMax age: 65 Years

Medical Language ↔ Plain English

Eligible for full intensity bone marrow transplant (BMT) conditioning but who lack a 6/6 HLA idential sibling donor

Locations (1)

University of Michigan Cancer Center

Ann Arbor, Michigan, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.